Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levosartan Plus
- Development stage
- Unknown
- Lead developer
- AHN-GOOK PHARMACEUTICAL
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Levosartan Plus** is an oral fixed-dose triple antihypertensive combination developed by Ahn-Gook Pharmaceuticals under the development code **AG-1705** and initially studied as **AGSAVI**. It combines S-amlodipine, a dihydropyridine calcium-channel blocker; valsartan, an angiotensin II type 1 receptor blocker; and indapamide, a thiazide-like diuretic. The product was developed for essential hypertension inadequately controlled with the S-amlodipine/valsartan doublet, completed Phase III development, received South Korean regulatory approval, and was launched in 2026. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05503953))
- Brand names
- Levosartan Plus
- Other names
- AGSAVIS-amlodipine + valsartan + indapamide
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)LTCC (Voltage-gated calcium channel (L-type))CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Levosartan Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Levosartan Plus.